Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.63 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.56 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.56 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12757602 | 0.88 | CES1 (0.81) | ALDH1A1CES1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL18395077 | 0.88 | CES1 (0.81) | ALDH1A1CES1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL25132396 | 0.87 | ALDH1A1 (0.74) | PPIAALDH1A1CES1PGRMEN1 | |
| SCHEMBL15840711 | 0.87 | ALDH1A1 (0.74) | PPIAALDH1A1CES1PGRMEN1 | |
| SCHEMBL15840818 | 0.86 | PPIA (0.74) | PPIAALDH1A1CES1MEN1KMT2A | |
| SCHEMBL15840715 | 0.83 | PPIA (0.70) | PPIAALDH1A1CES1PGRMEN1 | |
| SCHEMBL8956193 | 0.83 | CNR1 (0.70) | ALDH1A1CNR1MEN1KMT2AMAPT | |
| SCHEMBL11060530 | 0.83 | CNR1 (0.70) | ALDH1A1CNR1MEN1KMT2AMAPT | |
| SCHEMBL15840807 | 0.82 | ALDH1A1 (0.74) | PPIAALDH1A1CES1MEN1KMT2A | |
| SCHEMBL15840678 | 0.82 | MAPT (0.72) | PPIAALDH1A1CES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | PPIA 1884/4885ALDH1A1 4348/4885CES1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.